Advertisement
JERUSALEM, February 15, 2011 /PRNewswire-FirstCall/ -- Medisafe 1
Technologies Corp. (OTCBB:MFTH), a developer of patented technologies that
physically prevent unauthorized administration of prescription medications,
has been contacted over the past few weeks by several global medical
technology companies for potential cooperation.
For these companies, that have strong leadership in developing, manufacturing and selling medical supplies, devices, laboratory instruments, and diagnostic products to the US and global healthcare market, Medisafe's proprietary locking devices would be a valuable and complementary addition to their existing product range.
"The current discussions focus on how our patented product concept and technology could benefit our potential partners," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We are also discussing our mutual goals and areas of interests for potential cooperation. We will inform our shareholders within a few weeks of our progress."
Medisafe 1 Technologies' patented syringe locking device helps to reduce the number of injuries and deaths related to improper administration of medications.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
For more information, visit http://www.medisafe1.com
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Advertisement
For these companies, that have strong leadership in developing, manufacturing and selling medical supplies, devices, laboratory instruments, and diagnostic products to the US and global healthcare market, Medisafe's proprietary locking devices would be a valuable and complementary addition to their existing product range.
"The current discussions focus on how our patented product concept and technology could benefit our potential partners," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We are also discussing our mutual goals and areas of interests for potential cooperation. We will inform our shareholders within a few weeks of our progress."
Medisafe 1 Technologies' patented syringe locking device helps to reduce the number of injuries and deaths related to improper administration of medications.
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
For more information, visit http://www.medisafe1.com
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Media Contact:
Jacob Elhadad
CEO
+972-524440000
[email protected]
SOURCE Medisafe 1 Technologies Corp.